JP7074673B2 - エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター - Google Patents

エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター Download PDF

Info

Publication number
JP7074673B2
JP7074673B2 JP2018532435A JP2018532435A JP7074673B2 JP 7074673 B2 JP7074673 B2 JP 7074673B2 JP 2018532435 A JP2018532435 A JP 2018532435A JP 2018532435 A JP2018532435 A JP 2018532435A JP 7074673 B2 JP7074673 B2 JP 7074673B2
Authority
JP
Japan
Prior art keywords
group
endosomal
compound
formula
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018532435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503356A (ja
JP2019503356A5 (enExample
Inventor
ダブリュー． バネット、ナイジェル
ジェイ．エイチ． ポーター、クリストファー
コール、デレク
ヒックス、ギャレス
淳也 白井
ハースト、ギャヴィン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905333A external-priority patent/AU2015905333A0/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2019503356A publication Critical patent/JP2019503356A/ja
Publication of JP2019503356A5 publication Critical patent/JP2019503356A5/ja
Priority to JP2022078995A priority Critical patent/JP7458681B2/ja
Application granted granted Critical
Publication of JP7074673B2 publication Critical patent/JP7074673B2/ja
Priority to JP2024041282A priority patent/JP2024073581A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2018532435A 2015-12-22 2016-12-21 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター Active JP7074673B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022078995A JP7458681B2 (ja) 2015-12-22 2022-05-12 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
JP2024041282A JP2024073581A (ja) 2015-12-22 2024-03-15 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015905333A AU2015905333A0 (en) 2015-12-22 Modulators of Endosomal G Protein-Coupled Receptors
AU2015905333 2015-12-22
US201662291161P 2016-02-04 2016-02-04
US62/291,161 2016-02-04
PCT/US2016/068075 WO2017112792A1 (en) 2015-12-22 2016-12-21 Tripartite modulators of endosomal g protein-coupled receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022078995A Division JP7458681B2 (ja) 2015-12-22 2022-05-12 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター

Publications (3)

Publication Number Publication Date
JP2019503356A JP2019503356A (ja) 2019-02-07
JP2019503356A5 JP2019503356A5 (enExample) 2020-02-06
JP7074673B2 true JP7074673B2 (ja) 2022-05-24

Family

ID=59091175

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018532435A Active JP7074673B2 (ja) 2015-12-22 2016-12-21 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
JP2022078995A Active JP7458681B2 (ja) 2015-12-22 2022-05-12 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
JP2024041282A Pending JP2024073581A (ja) 2015-12-22 2024-03-15 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022078995A Active JP7458681B2 (ja) 2015-12-22 2022-05-12 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
JP2024041282A Pending JP2024073581A (ja) 2015-12-22 2024-03-15 エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター

Country Status (8)

Country Link
US (3) US11324832B2 (enExample)
EP (1) EP3393519A1 (enExample)
JP (3) JP7074673B2 (enExample)
CN (2) CN115531553A (enExample)
AU (3) AU2016377658B2 (enExample)
CA (1) CA3009325A1 (enExample)
EA (1) EA201891472A1 (enExample)
WO (1) WO2017112792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017018620A2 (pt) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. método de administração de tradipitanto, e, tradipitanto.
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
EA201892672A1 (ru) * 2016-05-20 2019-04-30 Такеда Фармасьютикал Компани Лимитед Лечение боли
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
IT202200018768A1 (it) * 2022-09-14 2024-03-14 Alberto Chiarugi Trattamento della nausea e vomito da chemioterapia
IT202200018780A1 (it) * 2022-09-14 2024-03-14 Alberto Chiarugi Modulatori degli effetti della chemioterapia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000247957A (ja) 1999-02-24 2000-09-12 F Hoffmann La Roche Ag ４−フェニル−ピリジン誘導体
JP2002537382A (ja) 1999-02-24 2002-11-05 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
JP2004504400A (ja) 2000-07-24 2004-02-12 エフ．ホフマン−ラ　ロシュ　アーゲー ニューロキニン１受容体アンタゴニストとしての４−フェニル−ピリジン誘導体
JP2004506718A (ja) 2000-08-08 2004-03-04 エフ．ホフマン−ラ　ロシュ　アーゲー ４−フェニル−ピリジン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
WO2005097199A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
JP2008505092A (ja) 2004-06-30 2008-02-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 立体選択的脱水によるα，β−不飽和エステル類および酸類
TW200606152A (en) * 2004-07-02 2006-02-16 Tanabe Seiyaku Co Piperidine compound and process for preparing the same
US9133116B2 (en) * 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2014168721A2 (en) * 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
JP6427491B2 (ja) * 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000247957A (ja) 1999-02-24 2000-09-12 F Hoffmann La Roche Ag ４−フェニル−ピリジン誘導体
JP2002537382A (ja) 1999-02-24 2002-11-05 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
JP2004504400A (ja) 2000-07-24 2004-02-12 エフ．ホフマン−ラ　ロシュ　アーゲー ニューロキニン１受容体アンタゴニストとしての４−フェニル−ピリジン誘導体
JP2004506718A (ja) 2000-08-08 2004-03-04 エフ．ホフマン−ラ　ロシュ　アーゲー ４−フェニル−ピリジン誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Angew. Chem. Int. Ed.，2013年，５２，１４２４７－１４２５１
Chem. Eur. J.，2010年，１６，１４４１２－１４４２３
J. Am. Chem. Soc.，2013年，１３５，８０５７－８０６２

Also Published As

Publication number Publication date
JP2024073581A (ja) 2024-05-29
JP2022113164A (ja) 2022-08-03
CA3009325A1 (en) 2017-06-29
EA201891472A1 (ru) 2018-12-28
AU2025201136A1 (en) 2025-03-06
EP3393519A1 (en) 2018-10-31
JP2019503356A (ja) 2019-02-07
CN108712913A (zh) 2018-10-26
WO2017112792A1 (en) 2017-06-29
AU2016377658A1 (en) 2018-06-21
CN108712913B (zh) 2022-06-24
AU2016377658B2 (en) 2022-09-29
CN115531553A (zh) 2022-12-30
BR112018012425A2 (pt) 2018-12-18
US11324832B2 (en) 2022-05-10
US20190000981A1 (en) 2019-01-03
AU2022291659A1 (en) 2023-02-02
US20230119819A1 (en) 2023-04-20
JP7458681B2 (ja) 2024-04-01
US20250235544A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
JP7458681B2 (ja) エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
KR102559975B1 (ko) 지방산 및 생체분자에 대한 접합에서의 이의 용도
US8809260B2 (en) β-arrestin effectors and compositions and methods of use thereof
JP7441246B2 (ja) 疼痛の治療
Hervé et al. Connexin-made channels as pharmacological targets
JP2018537529A (ja) プロテアーゼ活性化受容体２のモジュレーター
JP2021508692A (ja) プロテアーゼ活性化受容体−２の阻害剤
CN107406513A (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
US20250367266A1 (en) Oral pharmaceutical composition for prevention or treatment of osteoporosis containing teriparatide and method for preparation thereof
JP2022064920A (ja) 疼痛の治療のためのβアレスチン―ニューロキニン１受容体相互作用の阻害剤
BR112018012425B1 (pt) Composto tripartido, e, composição farmacêutica
JP2008509915A (ja) Ａβの効果を低減する方法およびそのための組成物
JP2023125435A (ja) 細胞膜非透過性の物質を動物細胞の細胞質に送達する新規キャリア分子
WO2016196750A1 (en) Beta-arrestin effectors and compositions and methods of use thereof
CN115361961A (zh) 通过上调人组织蛋白酶抑制素ll-37以抑制胰岛淀粉样蛋白多肽（iapp）自组装来预防或治疗胰腺功能障碍或糖尿病的方法
Gibbs An evaluation of the effects of activation of neuropeptide Y receptors on nociceptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220512

R150 Certificate of patent or registration of utility model

Ref document number: 7074673

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250